RecruitingPhase 4NCT07517796

I.V Papavrine for Labor Induction in Term PROM

I.V Papavrine for Labor Induction in Term PROM: A Prospective Randomized Controlled Trial

Sponsor

Western Galilee Hospital-Nahariya

Enrollment

110 participants

Start Date

Oct 22, 2025

Study Type

INTERVENTIONAL

Conditions

Premature Rupture of Membranes

Summary

This prospective randomized controlled trial aims to evaluate whether intravenous administration of papaverine 12 hours after term PROM reduces the interval from membrane rupture to delivery and improves maternal and neonatal outcomes. Researchers will compare drug papaverine to a placebo

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Papaverine arm and Placebo for people with premature rupture of membranes. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPapaverine arm

given 12 houres after rupture of membranes

OTHERPlacebo

I.V seline

Locations(1)

Galilee Medical Center

Nahariya, Israel, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07517796